Cargando…
Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
Mogamulizumab targets extracellular N‐terminal domain of CCR4, which is expressed in most adult T‐cell leukemia/lymphoma (ATL) cases. Recently, we reported that CCR4 C‐terminal gain‐of‐function mutations were frequent in ATL cases, and a subgroup with these mutations who were treated without allogen...
Autores principales: | Fujii, Keiichiro, Sakamoto, Yuma, Masaki, Ayako, Murase, Takayuki, Tashiro, Yukie, Yonekura, Kentaro, Utsunomiya, Atae, Ito, Asahi, Kusumoto, Shigeru, Iida, Shinsuke, Ueda, Ryuzo, Ishida, Takashi, Inagaki, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737778/ https://www.ncbi.nlm.nih.gov/pubmed/33022137 http://dx.doi.org/10.1002/cjp2.180 |
Ejemplares similares
-
CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022) -
Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014) -
Cutaneous adverse reactions and anti-tumor effects of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma
por: Yonekura, Kentro, et al.
Publicado: (2015) -
Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2020) -
Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)